

Treatment of wheezy infants with bronchodilators (comparison of inhaled ipratropium bromide versus inhaled salbutamol)

| | | |
|--|---|--|
| Submission date 12/09/2003 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol |
| Registration date 12/09/2003 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results |
| Last Edited 11/10/2016 | Condition category Signs and Symptoms | <input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year |

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Bangalore Satish

Contact details
Brighton & Sussex University Hospitals NHS Trust (RA)
Royal Alexandra Childrens Hospital
Dyke Road
Brighton
United Kingdom
BN1 3JN
+44 (0)1273 328145 ext. 2213
rah@mistral.co.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0051096269

Study information

Scientific Title

Treatment of wheezy infants with bronchodilators (comparison of inhaled ipratropium bromide versus inhaled salbutamol)

Study objectives

Infants with significant recurrent or persistent wheeze, who have a tendency towards atopy, will improve with inhaled ipratropium bromide.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised double-blind controlled cross-over trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied

Wheezing

Interventions

Comparison of inhaled ipratropium bromide versus inhaled salbutamol.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Ipratropium bromide, salbutamol

Primary outcome measure

Efficacy

Secondary outcome measures

Not provided at time of registration

Overall study start date

26/04/2001

Completion date

01/06/2003

Eligibility

Key inclusion criteria

Children aged 3 to 18 months with persistent or recurrent wheezing and atopic tendencies

Participant type(s)

Patient

Age group

Child

Lower age limit

3 Months

Upper age limit

18 Months

Sex

Both

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

26/04/2001

Date of final enrolment

01/06/2003

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Brighton & Sussex University Hospitals NHS Trust (RA)

Brighton

United Kingdom

BN1 3JN

Sponsor information

Organisation

Department of Health (UK)

Sponsor details

Richmond House

79 Whitehall

London

United Kingdom

SW1A 2NL

Sponsor type

Government

Website

<http://www.doh.gov.uk>

Funder(s)

Funder type

Government

Funder Name

Brighton and Sussex University Hospitals NHS Trust (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration